PRAX Stock Forecast & Price Target

Praxis Precision Medicine is supported by a compelling clinical profile in essential tremor, where ulixacaltamide showed consistent benefit across every TETRAS-ADL item, strong responder rates, and maintenance of effect in 55% of patients versus 33% on placebo, while clinicians at MDS 2026 were overwhelmingly positive and saw function as the key treatment goal. Its commercial case is strengthened by practical positioning ahead of propranolol and potentially before surgery, plus a broad unmet need reflected in more than 200,000 pre-screener respondents, roughly 30,000 pre-qualified referrals, and a population in which most respondents said half or fewer patients are adequately controlled. Beyond ET, relutrigine adds an attractive second growth driver, with Phase 3 EMBOLD showing 46% and 53% placebo-adjusted seizure reductions and a broader EMERALD program that could expand addressable DEEs, supporting a multi-shot pipeline with meaningful upside.

Praxis Precision Medicine is facing a challenging commercial profile because ulixacaltamide’s tolerability issues appear meaningful despite the absence of drug-related serious adverse events. Side effects were front-loaded during titration, but drug-related adverse events still led to discontinuation in 27.0% of Study 1 patients versus 1.7% on placebo, with dizziness and brain fog most often driving dropouts. Although faculty said discontinuations improved with better counseling and euphoric mood reports were brief sensory overstimulation at the 20 mg starting dose, the lack of quantitative evidence for that improvement leaves persistence, adherence, and eventual uptake uncertain.